Rigel’s R348 Fails in Phase II Study, Shares Down 13.6% – Analyst Blog

Rigel Pharmaceuticals, Inc. ( RIGL ) announced that its ophthalmic JAK SYK inhibitor, R348, failed to meet the primary and …read more

You may also like